Table 1

Baseline Demographic and Clinical Characteristics of the Study Patients (N = 758)

Age, yrs79.7 ± 6.2
Age group
 65–<75 yrs170 (22.4)
 75–<85 yrs417 (55.0)
 ≥85 yrs171 (22.6)
Female383 (50.5)
Nonwhite race97 (12.8)
Education < high school270 (35.8)
BMI group
 <18 kg/m223 (3.0)
 18–<25 kg/m2329 (43.5)
 25–<30 kg/m2270 (35.7)
 ≥30 kg/m2135 (17.8)
Heart failure status
 Ejection fraction <45%203 (43.2)
 NYHA functional class
  I22 (3.2)
  II462 (66.5)
  III173 (24.9)
  IV38 (5.4)
 ACE inhibitor use257 (40.7)
 Beta-blocker use99 (15.7)
Comorbid conditions
 Coronary artery disease463 (61.1)
 Chronic kidney disease280 (37.1)
 Diabetes mellitus193 (25.5)
 Stroke125 (16.5)
 COPD112 (14.8)
 Anemia111 (14.7)
Geriatric conditions
 Slow gait317 (41.8)
 Weak grip317 (41.8)
 Depression296 (39.1)
 Cognitive impairment264 (34.8)

Values are mean ± SD or n (%). All missing data <1%, with the exceptions of ejection fraction (37.9%), NYHA class (8.3%), and ACE inhibitors and beta-blockers (16.6% each). Percentages were calculated based on participants without missing data.

ACE = angiotensin-converting enzyme; BMI = body mass index; COPD = chronic obstructive pulmonary disease; NYHA = New York Heart Association.